Nymox (NYMX) Surges After New Prostate Cancer Clinical Trial Results Announcement

Shares of Nymox Pharmaceutical (NYMX) spiked more than 70% to $1.74 in early trading Monday after the company announced long-term clinical trial results from the company’s NX-1207 Phase 2 prostate cancer study NX03-0040. Nymox said the new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to […] View the full post at: Nymox (NYMX) Surges After New Prostate Cancer Clinical Trial Results Announcement Related posts: Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock